RapidPulse
RapidPulse
  • Home
  • Technology
  • Team
  • News
  • Clinical Trials
  • Investors
  • Careers
  • Contact
  • More
    • Home
    • Technology
    • Team
    • News
    • Clinical Trials
    • Investors
    • Careers
    • Contact
  • Sign In

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out


Signed in as:

filler@godaddy.com

  • Home
  • Technology
  • Team
  • News
  • Clinical Trials
  • Investors
  • Careers
  • Contact

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

More Complete Reperfusion with the RapidPulse® Aspiration System

Latest Headline

May 6, 2025 - GlobeNewswire

RapidPulse Announces Patient Enrollment Initiated in Pivotal Ischemic Stroke Study

“Across three studies evaluating this novel technology, operators achieved first-pass full reperfusion rates ranging from 60% to 69%—a substantial improvement over the 40% to 42% rates typically observed with current-generation devices,” said Marc Ribo, M.D. Professor of Neurology at Vall d’Hebron University Hospital.

Continue Reading

The rate of FPE (mTICI ≥2c after one-pass) was significantly higher in the RapidPulse-cohort than in the historical cohort (69% [20/29] vs. 28%; p<0.0001).


BMJ Journals - SNIS 2022

Archives

May 6, 2025


RapidPulse Announces Patient Enrollment Initiated in Pivotal Ischemic Stroke Study

May 6, 2025 | Source: GlobeNewswire

Continue Reading

December 11, 2024


RapidPulse Receives FDA Approval to Begin IDE Study in Ischemic Stroke Using Innovative Cyclic Aspiration System – Recently Completed Clinical Trial Shows Significantly Higher First Pass and Frontline Success Rates

December 11, 2024 | Source: GlobeNewswire

Continue Reading

April 4, 2024


Study Investigators Conclude RapidPulse® Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions

April 4, 2024  | Source: GlobeNewsWire

Continue Reading

May 31, 2023

 

RapidPulse investors extend Series A funding with $10M


The company is gearing up for FDA submission in the fourth quarter of 2023

May 31, 2023 

Continue Reading

May 24, 2023

 

RapidPulse Feasibility Study Results Presented at European Stroke Organization Committee Annual Meeting


Data from five hospitals showed FPE TICI≥2c rate was 60% with RapidPulse®...only 38.5% with standard aspiration

May 24, 2023  | ESOC 2023

Continue Reading

September 13, 2022

 

RapidPulse, developer of a device for treating strokes, raises $10.5M


Its technology may double the success rate of quick clot removal leading to better patient outcomes

September 13, 2022 | Source: Steven Loeb, vatornews

Continue Reading

September 13, 2022


RapidPulse Raises Funding for Ischemic Stroke Therapies

September 13, 2022 | Source: Endovascular Today

Continue Reading

July 28, 2022


First human use cases results show RapidPulse® enables doctors to get first pass effect results of TICI≥2c in 69% of cases…data presented at SNIS 2022

July 28, 2022 | Source: BMJ Journals

Continue Reading

June 28, 2021

 

Stroke device maker RapidPulse spins out of Syntheon incubator

June 28, 2021 | Source: Andrea Park, FierceBiotech

Continue Reading

June 23, 2021


RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy


Industry Veterans Join Team to Support the Development of Novel Cyclic Aspiration System for Ischemic Stroke

June 23, 2021 | Source: GlobeNewswire

Continue Reading

The RapidPulse™ System is not yet cleared for marketing by the US FDA. It is not available for commercial sale.

Copyright © 2021 RapidPulse, Inc. - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept